LivaNova PLC (LivaNova is a medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services aimed at improving patient outcomes. The company operates primarily in the medical technology industry, focusing on cardiopulmonary and neuromodulation solutions. These products are used in various heart-related medical procedures, including coronary artery bypass grafting and valve surgeries, and cater to neonatal, pediatric, and adult patients. The Neuromodulation segment provides devices for treating drug-resistant epilepsy (DRE) and treatment-resistant depression (DTD). The company offers its solutions to patients, healthcare professionals, and healthcare systems.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

LivaNova's R&D arm focuses on product design and development, including technology, AI, software, clinical study programs, and regulatory activities. The company aims to maintain or achieve technological leadership in its markets by developing technological enhancements, new uses for existing products, and less invasive technologies to address unmet patient needs. LivaNova engages researchers to collect clinical and health economic evidence to support regulatory filings and establish the value proposition for its products. The R&D units of LivaNova are located in the US, Brazil and Italy. These units are responsible for managing the company's research and development activities, focusing on maintaining technological leadership and ensuring the development of advanced and effective treatments. In FY2025, the company spent US$185.7 million on R&D, which as a percentage of revenue, stood at 13.6% and grew 1.8% YoY.